A
Academic organizations, role of 822
Accredited Social Health Activists 767
Acetaminophen 453
Activated prothrombin test 383
Acute encephalitis syndrome 483f
Adeno-associated virus 620
Adenosine diphosphate 673
Adjuvant vaccines, benefits of 178
Adjuvants concept 170
Adjuvants systems 177
Adjuvants under clinical investigation 180
Adolescent vaccines, mandatory 715b
Adverse drug reactions 808
Adverse events following immunization 25, 79, 105–107, 110–112, 114, 129, 142, 142f, 148f, 153, 153f, 356, 687, 750, 754, 776f, 779, 785, 798, 812
causality assessment 113
classification of 105
issue of 770
management of 108
prevention of 113
severe 106
Adverse events following pertussis vaccination 267
Adverse reactions following
tetanus vaccinations 244
Aerophobia 502
Agammaglobulinemia, X-linked 701
Agglutinin antibodies 270
Air currents, sensitivity to 502
Albert staining 285
Allergic diseases 136
Allergic disorder 696
Allogenic cell lines 553
Alpha-tocopherol 177
Amantadine 453
Amniotic fluid 633
Amoxicillin 296
Ampicillin 296
Anaphylactic reactions, history of 424
Anesthesia, local 503
Animal cell 364
Animal efficacy rule 537
Annual influenza vaccination 455
Anogenital epithelia 443t
Anorexia 230
Anti-angiogenesis therapy 555
Anti-B-cell antibodies 693
Antibiotic resistance 295
Antibody 46
adequate titer of 47
concentrate 33
containing products 694
dependent cellular
dependent enhancement 522
facilitate 42
levels, protective 48t
mediated vaccine immunity, mechanisms of 47
persistence of 389
principles of 84
Anti-C antibody titers 594
Anti-cytomegalovirus immune fluorescence antibodies 610f
Antidiphtheria 47
Antigenic drift 449
Antigenic shift 449
Antigenicity 761
Antihemagglutinin 51
Antimicrobial resistance 791
Antiseptics 503
Antitubercular treatment 110
Anti-varicella zoster virus 437f
Antiviral resistance 455
Appetite, loss of 532
Argentinian hemorrhagic fever 516
Aspartate aminotransferase 216
Aspirational district program 21
Aspirin 427
Assistant Commissioner Universal Immunization Programme 112
Association of Physicians of India 754
Ataxia 423
Atezolizumab 555
Auto-destruct syringes 135
Auto-disable syringes 19
Autologous tolerogenic dendritic cells 556
Autonomic dysfunction 502
Avelumab 555
Avian H5N1 influenza 451
Ayushman Bharat Program 29
Azathioprine 336
Azithromycin 286
B
Baboon studies 264
Bacillus Calmette-Guérin 5, 13, 15, 19, 34, 45, 46, 48, 59, 71, 74, 80, 82, 85, 86, 103, 118, 119, 119f, 123, 187, 204, 543, 620, 689, 697, 701, 702, 705, 708, 747, 767, 784–787, 789, 790, 838, 840
first dose of 189
primary infection, protective effect of 190
revaccination
protection by 190
strategies 190
vaccination strategies around world 191
Bacteremia, primary 400
Bacteria, enteric 467
Bacterial meningitis, probable 298t
Bacterial vectors 620
Basic reproductive rate 56
Bat rabies 506
Bell's palsy 445
Bifunctional fusion protein 670
B-immune responses 258
Bioadhesive delivery system 674
Bleeding disorders, vaccination of 75
Body's immune system 504
Bolivian hemorrhagic fever 516
Bovine calf serum 426
Bovine-human reassortant vaccine 327
Bradycardia 400
BrkAB system 254
Bronchial secretions 240
Brucella abortus 674
Brucellosis 158
Bull neck appearance 230
BvgAS system 254
C
Canadian Paediatric Society 842
Capsular polysaccharide 470
Carcinoembryonic antigen 552
Cefotaxime 296
Cell 168
activity 618
culture 521
based methods 763
infective dose 329
vaccines 501
frequency value, responder 433f
immunocompetent 669
Cellular response 351
Cemplimab 555
Central Bureau of Health Intelligence 66
Central Research Institute 15
Central Surveillance Unit 66
Cephalexin 296
Cerebellar abnormalities 633
Cervix 442
Chédiak-Higashi syndrome 336
Child survival safe motherhood 16
Children receiving steroids, vaccination of 709b
Chimera 487
Chinese hamster ovary cells 656
Chlorofluorocarbon 26
Chloroquine 508
Cholecystitis 401
control 510
diarrhea, culture-confirmed 511
enterotoxin, accessory 512
protect against 512
chain 512
traveler's risk of 741
vaccination against 511
killed oral 572
role of 513
Cholesteryl ester transfer protein 557
Circumsporozoite protein 531
Cirrhosis 216
Clarithromycin 286
Coccobacillus 253
Cochlear implant 84
Cold boxes 123
Coley's toxins 551
Coloboma 633
Colony-stimulating factors 708
Colorado Children's Immunization Coalition 842
Commercial sex workers 624
Communicable infections, spread of 99
Community based organizations 151f
Community Health Center 117
Complex regional pain syndrome 445
Comprehensive child survival strategy 29
Conjugated meningococcal vaccines 474
Conjunctivitis 67
Contingency plans 126
Contracted cowpox 4
Copaxone 556
Corpus callosum abnormalities 633
Coryza 67
Costimulatory molecules, triad of 555
Cotrimoxazole 296
Council of Medical Research-National Institute of Cholera and Enteric Diseases 578
Coxsackie 562
Cranial nerve dysfunction 502
Crimean Congo hemorrhagic fever 516
Cyclospora 568
disease burden
and seroprevalence 608
congenital 608
encoded proteins 611t
incidence of 609f
infection 609
congenital 607
diagnosis of 608
natural history of 607
seroprevalence, maternal 607
vaccination 609b
administration of 609
development of 610
history of 610b
Cytosine phosphate guanine 612
Cytotoxic T cell responses 669
Cytotoxicity 700
D
Dais, training of 164
Delivery systems, particulate 659
immunity 522
infection
natural 525
past 521
risk of severe 525
severe 521
treatment for 521
vaccination 525
against 521
candidates 526t
characteristics of ideal 522
efforts for 524
future 524
initiative, pediatric 523
majority of 523
next-generation 525
Deoxyribonucleic acid 7, 168, 180, 294, 420, 488, 523, 526, 554, 597, 617, 619, 621t, 626, 628, 652, 657
recombinant 6
Developing Countries Vaccine Manufacturing Network 770
Diaphragm, paralysis of 231
Diarrheal diseases, vaccines against 567
DiGeorge syndrome 336
antitoxin 271
measles and pertussis, burden of 24f
nontoxic mutant of 473
prevention 234
reduced dose 81
surveillance for 64
efficacy of 291
pertussis-inactivated poliomyelitis, reduced 723
vaccine 289
third dose of 787
vulvovaginal 229
waning immunity of 285
Diphtheria, tetanus and acellular pertussis 85, 119, 175, 232, 258, 290, 300, 543, 546, 547, 702, 707, 708, 715, 828, 831
immunization 42
combined with 544
Direct fluorescent antibody 286
Direct-drive technology 119
Directorate General of Health Services 803
Disease control spectrum 156
Disease frequency, measures of 55
Disposable delivery kits, supply 164
District Immunization Officer 112
District Surveillance Units 66
Dog bite 506
Dog kidney, primary 523
Down's syndrome 642
Doxycycline 571
Dracunculus medinensis 160
Drowsiness 532
Drug addiction 6
Durvalumab 555
E
Echovirus 562
Egg allergy 518
Electron microscopy 568
Electronic vaccine intelligence network 18
Enanthems 563
Encephalomyelitis, acute disseminated 518
Endemic disease 55
Endemic meningococcal disease 475
Endophthalmitis 468
Entamoeba histolytica 568
Enterotoxin 91
Enteroviral disease, clinical spectrum of 563
Enteroviral infections 563
Envelope glycoproteins 611
Enzyme immunoassay 593
Epithelial cells, microfold 88
Equine rabies immunoglobulin 503
diarrhea-associated hemolytic 573
enteroaggregative 573
enterohemorrhagic 573
enteroinvasive 573
enteropathogenic 573
fimbrial tip adhesin vaccine, enterotoxigenic 574
vaccine, enterotoxigenic 575
Ethylenediaminetetraacetic acid 420
European Medicines Agency 179
Exanthems 563
Exosomes 673
Expert Committee for Travel Medicine 739
Extrafollicular reaction 36
F
Family Health Bureau 769
Febrile reaction 538
Feco-oral route 568
Federation of Obstetricians and Gynaecologists of India 28
Fermentation 6
Fluids, intravenous 453
Fluorescence-activated cell sorting 660
Fluorescent focus inhibition test, rapid 505
Fluoroquinolones 404
Follicular dendritic cells 32
Food-grade bacteria 674
Freund's complete adjuvant 175
Freund's incomplete adjuvant 175
Furazolidone 571
Fusogenic liposomes 671
G
Ganglioside receptor ligand 675
Gastrointestinal disease 707
Gelatin allergy 518
Genealogy 253
Genetic detoxification 278
Genome 600
Gentamicin 296
German measles 360
Germinal center reaction 36
Ghana Food and Drugs Authority 842
Glatiramer acetate 556
Glaucoma 361
criteria and website evaluation process 841
Global Benchmarking Tool 808
Global Enteric Multicenter Study 325
Global Rotavirus Vaccine 339
Global Vaccine Market 747
Glutamine 333
Glutathione-S-transferase 603
Glyceraldehyde-3-phosphate dehydrogenase 49
Glycolic acid 669f
Gram Swaraj Abhiyan 21
Gram-positive enhancer matrix 674
Gray matter heterotopia 633
Griscelli syndrome 336
Guangxi Zhuang autonomous region, parts of 407
Guinea ebola 539
Guinea pigs, inoculation of 130
H
H antigens 569
H3N2 731
Haemophilus influenzae B 19, 27, 33, 48, 73, 81, 134, 173, 175, 194, 204, 232, 242, 293–300, 301f, 302, 303, 303f, 306t, 333, 409, 410, 470, 543–547, 655, 701, 702, 706–708, 737, 739, 774, 785, 786, 840
antigen 295
clinical features 294
invasive 301
meningitis 302t
Hand, foot, and mouth disease 564f
Hank's salts 333
Harmattan meningitis 468
Hashimoto's disease 445
Health and Family Welfare 803
Health Policy 798
Hearing loss 378
Helper cells 168
Hemagglutination assay 517
Hematology and oncology, pediatric 703
Hemolytic uremic syndrome 573
Hepadnaviridae 215
Hepatic failure, fulminant 382
diagnosis of 383
disease 391
atypical presentations of 383b
complications of 383b
human 383
prophylaxis for 387t
single dose of 393
vaccination 690
dose of 393
efficacy of 391
single dose of inactivated 393
Hepatitis B 4, 33, 41, 67, 72, 79, 85, 118–120, 123, 134, 173, 214, 216, 300, 424, 517, 543–547, 690, 702, 705, 707, 715, 724, 737, 784, 789, 813
core antibody 216
role of 223
infection
chronic 216
prevent 223
vaccination 225
adverse effects of 220
routine 219
intradermal administration of 221
infection 388
chronic nature of 588
natural history of 588
pathogenesis of 588
protective immunity against 589
proteins 591t
current 597t
strategies for 590
Hepatitis E virus 600
genome organization 600
vaccine
neutralization assay 603
oral immunization of 603
Hermansky-Pudlak syndrome 336
Herpangina 563
Histocompatibility class, major 594
Holoendemic disease 55
Horner's syndrome 363
Horse antitetanus serum 241
Human albumin 426
Human animal reassortant vaccines 327
Human calciviruses 568
Human candidate vaccine 529
Human cell cultures, inoculation of 130
Human diseases, control of 155
Human immunodeficiency virus 3, 7, 31, 32, 55, 84, 88, 95, 107, 167, 180, 190, 295, 302, 307, 314, 330, 336, 352, 363, 377, 388, 424, 454, 476, 508, 551, 589, 617, 618f, 619, 621t, 656, 666, 701, 702, 729, 747
development of 619b
Human interleukin, recombinant 612
Human metapneumovirus 651
Human neonatal oral rotavirus vaccine 328
Human papillomavirus 18, 33, 81, 84, 85, 173, 175, 204, 442, 444, 551, 609, 656, 668, 702, 706, 747, 760, 771, 772, 792, 800, 840
classification of 443t
infection 443
role of 442
vaccination 712
development, history of 443
dosage 444
epidemiological effects of 445
epidemiology 442
indications 444
nonavalent 443
pathogenesis 443
prophylactic 443
schedule 444
single dose of 446
virology 443
Human parainfluenza virus 650
candidate vaccines 652
vaccines 652
live attenuated 652
virion and genome organization 651f
Human respiratory tract 274
Humanized monoclonal antibody 643
Humoral response, persistence of primary 38
Hydrolyzed gelatin 426
Hydrophobic protein, small 638
Hydroxychloroquine 508
Hyperendemic disease 55
Hypersalivation 502
Hyperventilation 502
Hypothalamic-pituitary-adrenal axis 693
I
Ileocolitis 349
Imiquimod 676
Immune
checkpoint inhibitors 555
correlate 540
disorders, history of congenital 424
electron microscopy 323
serum globulin 362
suppression 552
therapy 555
Immunisation Advisory Centre 843
Immunity 207
acquired 100
adaptive 89
against pertussis 276
inborn errors of 51
long-term persistence of 489
Academy 843
adult 290
advancing maternal 726
annual 461
anxiety-related reaction 107
clinic, safety in 135
contraindications of 71
coverage 766
during illness 696
error-related reaction 106
expanded program on 7, 9, 15, 16, 19, 73, 79, 86, 194, 203, 204, 219, 274, 284, 308, 330, 362, 485, 639, 711, 726, 732, 746, 774, 784, 798, 812, 827
intensification of routine 21
lactation 693
practices 79
advisory 327
pregnancy 691
primary 490
programs 798
purpose of 78
role of 105
safety 133
schedule 78
ideal 78
multi-dose 525
timetable 81t
vaccines 509
Immunocompromised hosts 304
Immunogenic proteins 137t
Immunogens, antibody based 622t
Immunostimulatory sequences 177
Immunosuppressant drugs 695
Immunotherapy, adoptive 585
In vitro markers, tests for 130
India Strategy Women Adolescent Child Health 29
India's National Guinea Worm Eradication Programme 160
Indian Academy of Pediatrics Committee on Immunization 291
Indian Neonatal Strain Vaccine 328
Indian Public Health Association 25
Indian Society of Nephrology 28
Indian Vaccine Grand Challenge Program 757
Indian Vaccine Industry 747
Indian Vaccine Market Report and Forecast 748
Indirect fluorescent antibody 640
Infant immunization, reciprocal interference of 271
Infected animals, bite of 501
Infection 100
chronic 551
elimination of 158
natural 264
protection against 259
rate 56
spread of 99
viral 376
Infectious Diseases Society of America 336
Inflammatory disease, chronic 336
Inflammatory response, subdued 468
A 720
A viruses 448
antigenic subtypes of 450t
activity, start of 452
antigens 455
antiviral drugs for 453
B
burden of 448
lineage 455
biology of 448
circulation 452
diagnosis and symptomatology 453
epidemics and pandemics 449
H9N2 viruses 452
illness 455
immunization 460
history of 461
intranasal 34
morbidity to 449
mortality to 449
outbreaks 449
pandemics 449
mortality during 449
pediatric 453
season 456
subtypes 449
treatment of 454
types 449
Inoculation 11f
Insect cells, proteins expressed in 603
Integrated Disease Surveillance and Response Guidelines 404b
Integrated Disease Surveillance Program 62
Integrated Disease Surveillance Project 66
Intensive care units 238
Interferon 619
International Certificate of Vaccination 738f
International Conference on Harmonization 761
International Finance Facility for Immunization 769
International Study of Asthma and Allergies in Childhood 646
International Vaccine Institute 577
Intradermal vaccines, effectiveness of 508
Intraocular calcifications 633
Intussusception monitoring 343
Invasive disease 474
Inventory control system, maximum-minimum 125
Iodonaphthylazide 629
Ipilimumab 555
Isolation 104
J
Jacobson's case 812
Japanese encephalitis 18, 20, 27, 67, 76, 81, 84, 85, 129, 173, 478, 480, 482, 483f, 484, 484t, 492, 494, 494t, 692, 495, 496t, 698, 712, 724, 733, 737, 741, 746, 785, 825, 837, 840
age distribution of 484f
endemic states 482f
epidemiology of 494
large-scale 495
prevention 478
significance of 478b
revised 492
transmission 482
traveler's risk of 741
vaccination 495
campaign 785
coadministration of 493
inactivated 493
types of 496b
viral activity 480
transmission cycle of 479
Jeryl-Lynn strain, doses of 378
L
Lactation, vaccination during 75
Lactic acid 669f
Lactide-co-glycolides 668
Lactococcus lactis 674
Lanzhou lamb rotavirus 327
Laryngeal diphtheria 231
Lassa fever 516
Leningrad-Zagreb strain 378
Leprosy 158
Levamisole 708
Licensed Respiratory syncytial virus intervention products 643
Licensed zoster vaccine, dose of 435
Lidocaine 72
Limbs, paralysis of 231
Linked-epitope suppression 267
Lipid-encapsulated nanoparticle, consists of 634
Lipo-oligosaccharide 274
Listeria monocytogenes 306
Live attenuated cell culture 485
Loud noises 502
Luteinizing hormone-releasing hormone 668
Lymphocytic choriomeningitis virus 612
Lymphoma 426
Lymphoproliferative disease, X-linked 336
Lyssavirus 501
M
Macacus rhesus 519
Macacus sinicus 519
Macromolecular purification 6
Mannose-binding lectin 32
Mansonia mosquitos 480
Marburg and ebola fever 516
Mass vaccination 510
Maternal mortality rate 108
Matrix protein 638
Measles, mumps, and rubella 72, 81, 83, 85, 107, 111, 142, 173, 352, 362, 494, 546, 547, 688, 701, 702, 707, 708, 712, 715, 731, 767
vaccine 426
part of 375
Medical disorders, chronic 459
Medical Officers of Health 769
Medical Officers of Primary Health Centers 110
Medicines, immunosuppressive 816
Membranous nephropathy 216
Memory B lymphocytes 169
Memory T lymphocytes 169
Meningeal tuberculosis 189
conjugate vaccine 467
serogroup B vaccine, multicomponent 473
vaccination 476
vaccinology, recent advances in 474
Meningococcal polysaccharide
diphtheria toxoid conjugate vaccine 609
protein conjugate vaccines 470
quadrivalent 470
Meningoencephalitis 557
Metabolic disorder 696
Metastatic abscess 401
Metastatic colorectal cancer 555
Microbial tests 761
Microcephaly 632
Microorganism, single 4
Miliary tuberculosis 189
Molecular biology 6
Mononegavirales 638
Mononucleosis, infectious 582
Monosodium l-glutamate 426
Monovalent and combination formulations, development of 4
Moreau strain 188
Mortality 84
Mosquirix 529
Mucous membranes 32
Multicenter acellular pertussis trial 258
Multidisease 4
Multifactorial causation 57
Multiple organ system failure 518
Multiple puncture technique 189
active immunization 376
attack rate of 377
efficacy and effectiveness 378
encephalitis 375
immunogenicity 376
incidence of 376
infection 378
measles, and rubella 705
passive immunization 376
safety 378
development 376
virus 376
Mumps/measles, mumps, and rubella vaccine 715
Muscle fasciculations 502
Myalgia 518
Myelos 94
Myocardium 516
Myxoviruses 620
N
Naïve b-cells 36
Nanoparticle vaccines 557
Nasal diphtheria, anterior 230
Nasopharyngeal carcinoma 582
Nasopharyngeal carriage 305
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases 843
National Control Laboratories 808
National Guinea Worm Eradication Programme 160
National Health Policy 29
National Health Service 829
National Immunization Advisory Committees 799
National Immunization Days 17
National Infant Immunization Coverage 17
National Institute of Cholera and Enteric Diseases 511
National Library of Medicine 831
National Network for Immunization Information 830
National Pertussis Immunization Policy 275
National Public Health Surveillance Project 65
National Regulatory Bodies 767
National Security 84
National Smallpox Eradication Program 15
National Technical Advisory Group of Immunization 19, 25, 195, 301, 493, 716, 749, 754b, 775, 775f, 798, 799, 801–805, 812
functions 806
meetings 805
secretariat 804
subcommittees 803
National Travel Health Network Centre 739
National Vaccine Campaign 820
National Vector Borne Disease Control Programme 480
Natural killer T-cells, invariant 50
Navy Medical Research Institute 570
Necrotizing vasculitis 216
Neisseria lactamica 467
Nelms’ cowpox pustules 4
Neoantigens 554
Neonatal care 164
Neonatal immunization 273
Neonatal pertussis 252
Neonatal vaccination 273
Neoplasms, malignant 701
Nervous system, signs of 501
Neuraminidase 175
Neurological disease 519
Neuromuscular disease 642
Neuropathy 423
Neuropsychiatric sequelae, permanent 478
Neurotoxin disease 518
Neurotropic disease 518
Neurovirulence 420
Newcastle disease virus 585
N-glycosylation 603
Nicotinamide adenine dinucleotide 294
Nikshay 68
Nivolumab 555
Non-Culex species 480
Noninfectious conditions 555
Noninfectious diseases 551
Non-polio enteroviral infections 563
Nonreplicative adenovirus vector 523
Novel antigen candidate vaccines 577
Novel development strategies 90
Nucleotide polymorphism, single 399
Numerous immunogenicity 258
O
O-antigen 576
Ocular diphtheria 229
Ocular infections 563
Oil-in-water emulsions 175
Oka strain 419
Oka-Merck strain 419
Oligodeoxynucleotide 677
Onchocerciasis (River Blindness) Elimination Program 160
Oncofetal antigens 552
Oncogene products, mutated 552
Optic neuritis 627
Oral cholera toxin 512
Oral fluids 453
live-attenuated 95f
Oral polio virus 194
vaccine 16, 19, 58, 74, 80, 90, 101, 110, 130, 203, 204, 210, 212, 328, 332, 333, 543, 661, 688, 690, 701, 705, 840
doses of 210t
early history of 207
live 203
schedules of trivalent 211
Oral typhoid 701
Orthopneumovirus 638
Oseltamivir 453
Outpatient department 650
Overwhelm immune system 136
P
Pachygyria 633
Packed red blood cells 694
Pain 532
Palivizumab 643
Papanicolaou smear 443
Paracetamol 453
Paralytic disease 198
Paralytic ileus 240
Paralytic polio 196
Paramyxoviridae 375
Paramyxoviruses 620
Paraplegia 207
Parasites, blood stage 533
Parenteral rotavirus vaccine 329
Parenteral transmission 215
Passenger antigen ovalbumin 673
Path's vaccine resource library 843
Pathogen adaptation 267
Pediatric cancer 705t
Pediatric Societies, role of 373
Pediatrician in office practice, role of 114
Pembrolizumab 555
Penicillin 231
Penta- and hexavalent combinations 232
Peptide 551
Peramivir 453
Pericardial effusion 563
Periodic mass vaccination campaigns 510
Periorbital cellulitis 468
Peripheral neuropathy 245
and rubella vaccines, adverse effects of 129
antigen 267
components, role of 261
disease 273
substantial portion of 251
immunity 249
immunization, widespread 277
in adolescents and adults 251
incidence of 262
infection and vaccination 265f
mortality 277
pathogen of 253
pathogenesis of 253
protection against 271
schedule, primary infant 272
strains 267
transmission of 272
approaches, new 274
coverage of 275
doses of 275
in office practice, use of 275
live attenuated 278
schedule for 276
Petechiae 563
Phagocytic function disorders 701
Phagocytic syndrome 401
Pharyngeal diphtheria 230
Pharyngeal spasms 502
Photophobia 431
Pichia pastoris 603
Picornaviruses 620
Placenta 720
Plague 784
Plant-derived triterpene glycoside 436
Plaque forming units 420
Plaque reduction neutralization test 516
Plasmid deoxyribonucleic acid 657
Plasmid vector 521
Pleocytosis, asymptomatic 375
Pleurodynia 563
Plotkin's nomenclature 46
Pneumococcal infections 662
Pneumoviridae 638
burden of 24f
elimination 28
timeline of 17f
eradication 97
end game 212
information system 164
third dose of 786
traveler's risk of 742
under global eradication 197
campaign 785
injectable 289
modern inactivated 197
disease 195
high affinity for 95f
infection 195
epidemiological features of 196
mucosal immunity to 93
pathogenesis 93
receptor 93
replication 95f
doses of inactivated 200t
early history of inactivated 197
efficacy of modern inactivated 198
fourth-generation inactivated 201
fractional-dose inactivated 838
inactivated 20, 75, 80, 81, 83, 85, 93, 94, 103, 194, 198, 199t, 200, 201, 203, 173, 242, 300, 543, 544, 547, 661, 689, 690, 702, 706–708, 781, 840
safety of modern inactivated 198
schedule, onactivated 96f
vaccine, inactivated 546
Polyepitope 594
Polylactic-co-glycolides acid 669
Polymerase protein 651
Polymeric lamellar substrate particles 670
Polymers, biodegradable 668
Polyphosphazene polyelectrolyte 669
Poor hygiene 570
Porcine circovirus 337
Porencephaly 633
Pork tapeworm 158
Postimmunization antibody 254
Postimmunosuppressive therapy 701
Postsplenectomy 701
Post-transplantation lymphoproliferative disease 585
Postural orthostatic tachycardia syndrome 445
Postvaccinal encephalitis 518
Postvaccination testing, routine 222
Potency tests 761
Prednisolone 708
Prednisone 336
Predominant immune responses 33t
Pregnant travelers, vaccination for 737
Premembrane 632
Prilocaine 72
Primary Health Center 117
Private sector and vaccination 27
Program for Appropriate Technology in Health 757
Program implementation and monitoring 750
Prokaryotic system, proteins expressed in 603
Promoting public-private partnership 750
Prophylactic B- and T-cell combined vaccines 593
Prostatic acid phosphatase 553
Protection, surrogate of 47
Protective immunity, newer concepts of 621
Protein
conjugate polysaccharide vaccines 691
conjugate vaccine 470
derivative, purified 190
fimbrial 262
glutamate-rich 674
latent 584
nonstructural 611
structural 611
vaccine, subunit 523
Pseudotumor cerebri 401
Pteropodidae family 536
Public education 245
Pulmonary artery stenosis, branch 369
Pulmonary edema 530
Pulse Polio Program 820
Pyrexia 240
R
Rabbit myelin bound protein 137
Rabid animals 502
in animals, signs of 502
monoclonal antibody 503
traveler's risk of 741
vaccination, intradermal 507
availability of 508
egg-based 505
first dose of 506
intradermal administration 504
neutralizing antibody 508
Radiation therapy 84
Randomized clinical trials 189
Rapid replication rate 619
Rashes, urticarial 216
Rational antigen discovery 659
Reactions, vaccine related 105
Reactogenicity 437
Recurrent disease 427
Red blood cells 533
Regulatory natural killer 552
Renal disorder 696
Renin-angiotensin system 558
Replication-defective virus vaccine 613
Reproductive and child health 16
Respiratory airways 264
Respiratory disease 643
Respiratory epithelium 262
Respiratory symptoms 375
F vaccine 644
genome and morphology 638f
global burden of 640f
intravenous immunoglobulin 643
molecular epidemiology of 640
products’ landscape 643
vaccination strategies 643
vaccine, pediatric 643
Resuscitation kit 135
Retinitis 361
Retinoic acid-inducible gene 95
Retrobulbar neuritis 627
Rhabdoviridae 501
Rhabdoviruses 620
Rhesus human reassortant vaccine 327
Rheumavax 556
Ribosomal entry site, internal 630
Rickettsial infections 401
Rift valley fever 516
Rimantadine 453
Risk interval analysis 133
Risus sardonicus 239
Rituximab 336
Rotarix™ 329
Rotary lancet 15
classification 324
working group 325
disease 663
epidemiology 325
gastroenteritis 326
pathogenesis of 326
structure 324
and intussusception 342
development 326
effectiveness of 338
efficacy of 338t
monovalent human G1 328
nonreplicating 329
vaccination with current licensed 329
antibody 361
complication of 369
containing vaccine 365
eradication of 371
incidence of 365f
measles, and varicella 694
panencephalitis, progressive 360
significance of 360
specific antibodies 361
vaccination 365
global coverage of 364f
Rubulavirus 375
Russian Federal Ministry of Health 539
S
Sabin strains 203
Safe injections 134
Safeguard power source 121
Safety assessment 179
Saint Louis encephalitis virus 479
Saliva 633
Sanitary departments 12
Sapovirus 568
Scare-related adverse events, vaccines 108
Schistosomiasis 158
Schizencephaly 633
Sclerosing panencephalitis, subacute 348
Seasonal flu 6
Secretory antibodies 94
Selecting proper media 143
Sendai virus 652
Sensorineural deafness 369
Sensorineural hearing loss 607
Sentinel surveillance 65
Sepsis 109
Septicemia, fulminant 467
Seroconversion index 209f
Seropositivity 57
Seroprotection 57
Sexual transmission 215
Sexual transmitted diseases 215
Shellfish 570
Shiga toxin-secreting Escherichia coli 573
Shigellosis 575
Shingles prevention study 434
Sickness rate 126
Simultaneous vaccines 543
Sinusitis 293
Situation analysis 750
Skeletal muscle paralysis 205
before vaccination 10
disease, eradication of 155
eradication 15
timeline of 15t
vaccine 146
virus 11
zero, operation 16
Social and political criteria 159
Socioeconomic status 608
Sodium chloride 426
Sodium phosphate dibasic 426
Soft palate, paralysis of 231
Solar direct-drive refrigerators 120
Sorbitol 426
Spatula test 241
Special groups, vaccination of 685
Splenic hypofunction, vaccination in 709t
Spontaneous reporting systems 132
Sporozoites 531
Standard material transfer agreement 771
State surveillance units 66
Stem cell transplant, hematogenous 609
Sterile technique 71
Stevens-Johnson syndrome 423
Stomatitis 349
Stool shedding, preventing 93
Strain distribution 325
Strengthen service delivery 164
Strengthen vaccine preventable disease surveillance system 28
Structural capsid 479
Sudden infant death syndrome 288
Surveillance Medical Officers 65
Surveillance system 65
Swine flu 457
Systemic dendritic cells 667
Systemic lupus erythematosus 551
Systemic symptoms, mild 457
Systems strengthening 152
T
abnormalities, congenital 426
dependent process 31
immune responses 258
immunodeficiencies, severe 701
independent
antigens 31
immunity 409
vaccines 474
intraepithelial 90
line-adapted 619
receptor 8
receptor peptide
vaccination 556
vaccines 8
resident memory 264
response 46
vaccines with 592
vaccines 551
T-cytotoxic cells 33
T-dependent antigens 38
Temperatures, monitoring of 123
Tetanospasmin 287
and reduced diphtheria dose vaccine 232
diagnosis of 240
generalized 239
immunoglobulin 241
low-dose diphtheria vaccine 289
pertussis, and influenza 725
reduced dose diphtheria 85
Tetanus toxoid 16, 19, 64, 80, 118, 123, 134, 225, 227, 232, 242, 247f, 257, 261, 287, 289, 302, 473, 701, 702, 712, 746, 805, 838
containing vaccines 722
doses, history of 290
in pregnancy 289
in wound management 290
single antigen 242
single-dose 669
vaccine 289
Tetracycline 571
T-follicular helper cells 612
Thiosulfate-citrate-bile salts-sucrose 571
Thymus disease 518
Tobacco addiction 558
Tolerogenic dendritic cell vaccines 556
Tolerogenic vaccines 551
Tonsillar diphtheria 230
Total leukocyte count 618
Towne vaccine 613
Towne-Toledo chimera vaccines 613
Transcutaneous immunization 676
Transcutaneous vaccine delivery 676
Transmembrane toll-like receptors 168
Travelers, immunization for 697
Traveling vaccinators 12
Tripolyphosphate 675
Trumenba 473
cases, notification of 68
infection, latent 187
prevention trials 13
surveillance of 68
vaccines 187
Tumor microenvironment 552
Ty21a vaccine 406t
bacilli 400
diagnostics 397
epidemiology 397
causes of 399
diagnosis 401
estimated global disease burden of 398f
traveler's risk of 741
vaccines, new-generation 405t
Mary 398
surveillance 402
treatment 397
acceleration consortium 410
Typhus 516
U
Unbound toxin, neutralization of 241
Uniform Immunization Schedule 812
United Nations Development Program 747
United Nations Environmental Program 772
United Nations Fund 370
United Nations Millennium Development Goals 284
Universal Health Coverage 29
Universal Immunization Program 9, 16, 18b, 19t, 79, 106, 123t, 195, 211, 233, 242, 284, 348, 375, 483, 745, 746, 774, 776f, 783, 799, 803
evolution of 18t
new antigens in 27
newer vaccines in 753
schedule 837
Universal Mass Vaccination 290
Universal Pertussis Vaccinations 249
Uveitis, anterior 627
V
adolescent 219
aim of 59
before departure, timing for 740
behavior continuum 147f
document 738
during pregnancy 75
for travelers, required 740
historical background of 784
maternal 271
misinformation about 128
negative effects of 103
purpose of 217
rationale behind 269
strategies for travelers 735
timing of 736
travel 515
value of 783
Vaccine 4, 31, 84, 116, 128, 299, 334, 338, 341, 351, 362, 511, 521, 542, 568, 569, 571, 574, 576, 606, 617, 626, 632, 650, 689, 704, 708, 724, 753f, 783, 798, 824, 829
adhesin-based 574
and logistics, managing 125
dose of 49
nature of 48
anti-idiotype 554
associated virus, transmission of 424
attenuated 628
bonds 770
campaigns 785
packing of 125
choice of 268
communication 140
new methods in 140
reframing of 151
composition of 602
cost of 821
coverage, descriptive analysis of 786
decade of 765
delivery
and immune response, method of 667
methods, alternative 666
history of 361
new technologies in 654
newer approaches in 602
stages of 759t
discovery 655
strain-specific 337
estimates 487t
enteric 567
primary 58
reasons for 219
first dose of 79
for travelers 737t
formulations 443
freeze-sensitive 121
freeze-tolerant 121
communication 151b
determinants of 148
factors influencing 149f
missed opportunity and 372
spectrum 147f
understanding 147
history of 3
immunogenicity 57
and efficacy 317
immunology 31
in ice-lined refrigerators, storage of 125
candidate 614
incidence guidelines 830
indirect effect of 305
induced immunity 50
mediators of 46
current status 747
interactions 84
intramuscular 672
killed 336
knowledge project 843
liquid 188
live
logistics 26
steps in 761
monomeric 584
multimeric 584
multipeptide 553
multiple 736
new 17
new-generation 405
open vial policy 134
scope of 749
presentation 781
pressure 267
preventable disease 16, 64, 78, 128, 129, 129t, 146, 153, 164, 284, 448, 703, 748, 753, 798, 829, 830
monitoring system 239t
samples collection of 68
surveillance 64
surveillance, steps for establishing 66
surveillance, types of 65
pricing strategies 760
production and distribution 117
protein-based 554
purified formalin inactivated 636
reactions, minor 106t
recombinant 656
recommendations 733
refrigerator
recognize individual 121
research and development 750
responses
cell mediated 49
suboptimal for 87
risk communication 137
routine childhood 33t
and quality 779
evaluation of 179f
misconceptions about 136
misinformation about 136
net members 842
network 135
of combination 4
post-licensure evaluation of 132
prelicensure evaluation of 130
scheduling of 78
security 781
sensitivities of 118f
heat and cold 118t
shedding 330
single-dose 669
soluble pentameric 614
storage 125f
and handling 428
pattern 122f
protocol for 135
substrains of 188
candidate 578
peptide 656
technologies, range of 522
testing, stages of 131t
transmission-blocking 529
transportation of 117f
travel 733
trials 130
phases of 130
true adolescent 712
under research 634
use of 411
reading stages of 123
viral vectored 657
virus transmission 488
Vagina 442
Vapocoolant 72
breakthrough 421
containing vaccines 421
disease 425
serious 422
epidemiology of 422
history of 426
infection 423
syndrome, congenital 424
vaccination 427
contraindications for 424
cost-benefit of 422
effect of 422
effectiveness of 421
efficacy of 420
single-antigen 426
virus, strains of 425
diagnosis of 431
glycoprotein E 436
infected cells 436
infections, treatment of 432
specific immune responses 434f
Variolae vaccinae 11
Vector-borne diseases 522
Venezuelan hemorrhagic fever 516
Ventriculomegaly 633
Vesicular stomatitis virus 538
Vietnam's program 407
Viral antigens 552
Viral fever, hemorrhagic 516
Viral pathology, reduced 8
Viremia, mild 517
Virosomes 175
Virus 215
alpha 620
evolution 343
neutralizing antibodies 486
shedding and transmission 206
vaccine 617
Viscerotropic disease 518
Vulva 442
W
Waning immunity 249
Waterhouse-Friderichsen syndrome 468
Water-in-oil emulsions 175
West-Nile fever virus 515
White blood cell 294
Whole-cell 572
cancer vaccines 553
heat-killed 510
monovalent vaccine 572
only vaccine, modified killed 572
oral cholera vaccine, killed 512
priming 264
recombinant B 572
inactivated 405
killed oral 741
Wild virus, recombinants with 613